Wiesner Healthcare v. Schedule A Defendants: Default Judgment on Male Incontinence Clamp Patents
Wiesner Healthcare Innovation LLC secured a default judgment against 21 e-commerce defendants operating on Amazon, eBay, Temu, and Walmart for willful infringement of three patented external male incontinence clamp designs. The court awarded $37,816.91 per defaulting defendant — including trebled damages and attorney’s fees — closing the case in just 160 days.
E-commerce clamp infringers face treble damages and permanent injunction
Filed on 8 May 2024 in the Illinois Southern District Court before Judge Sharon Johnson Coleman, this action was brought by Wiesner Healthcare Innovation LLC against a Schedule A roster of anonymous e-commerce sellers operating storefronts on Amazon, eBay, Temu, and Walmart. The complaint alleged willful infringement of three federally registered patents — US10624728B2, US11351020B2, and US11642205B2 — all covering external male incontinence clamp products, alongside trade dress infringement and Illinois common law claims of unjust enrichment and unfair competition.
The case concluded on 15 October 2024 via default judgment after none of the 21 defaulting defendants answered or appeared. The court found personal jurisdiction on the basis that defendants actively targeted Illinois consumers through interactive e-commerce stores offering U.S. shipping. Damages were computed as a $10,000 reasonable royalty per defendant plus $2,380.95 in hypothetical negotiation transaction costs, with both sums subsequently trebled under 35 U.S.C. § 284, resulting in a total of $37,816.91 per defendant including attorney’s fees.
The 160-day resolution is consistent with the accelerated timelines typically seen in Schedule A e-commerce enforcement actions, where default is the norm rather than the exception. The willfulness finding — supported by claim chart evidence and screenshot documentation — enabled trebling and an exceptional case fee award, maximising plaintiff’s recovery without contested litigation. The public record does not disclose the total funds actually recovered from frozen marketplace accounts, nor the identities of the specific defendants listed on Schedule A.
Filing to Default Judgment in 160 days
160 days from filing to default judgment — faster than the median patent case disposition in Illinois federal courts
Default judgment granted: what the ruling means for both parties
Default judgment: uncontested liability on all six counts
When defendants fail to appear or answer, the court may enter default judgment under Federal Rule of Civil Procedure 55. Here, all factual allegations — including willful infringement of three patents, trade dress infringement, and Illinois common law violations — were deemed admitted. The court independently verified personal jurisdiction and damages calculations before entering judgment, consistent with standard default judgment procedure in Schedule A patent cases.
Fed. R. Civ. P. 55 defaultWiesner secures treble damages and a permanent injunction
Wiesner Healthcare obtained a permanent injunction barring manufacture, sale, and importation of infringing products, plus $37,816.91 per defendant comprising trebled royalties, transaction cost damages, and attorney’s fees. Marketplace platforms including Amazon, PayPal, and Temu were ordered to freeze and release defendant funds within seven to fourteen days. The exceptional case finding under § 285 further validates Wiesner’s enforcement posture and strengthens its position in any future actions against similar infringers.
Full relief grantedNon-appearance results in maximum exposure for e-commerce sellers
By failing to respond, the 21 defaulting defendants forfeited any opportunity to contest validity, non-infringement, or damages quantum. Each now faces a permanent injunction, frozen marketplace accounts, and a judgment debt of $37,816.91 — collectible through ongoing supplemental proceedings under Fed. R. Civ. P. 69. The default also precludes relitigation of the admitted facts, making any future challenge to liability procedurally difficult without vacating the default itself.
Full liability admitted by defaultSchedule A enforcement: a replicable model for medical device IP owners
This judgment illustrates how patent holders with products widely counterfeited on e-commerce platforms can leverage Schedule A actions for rapid, cost-effective enforcement. The combination of preliminary injunction, account freezing via third-party providers, and default judgment creates strong deterrence. For competitors and marketplace sellers in the incontinence device space, this ruling signals that Wiesner’s patent portfolio is actively enforced and that marketplace presence alone is sufficient to establish jurisdiction in Illinois.
Active Schedule A enforcement postureFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Wiesner Healthcare Innovation, LLC | Company | Medical device IP holder — patents on external male incontinence clamp technologySearch in Eureka ↗ |
| Defendant | The Individuals, Corporations, Limited Liability Companies, Partnerships, and Unincorporated Associations Identified on the Attached Schedule A | Individual | Anonymous e-commerce sellers on Amazon, eBay, Temu, and Walmart — identified only on Schedule ASearch in Eureka ↗ |
| Plaintiff counsel | Benjamin Adam Campbell | Attorney | Counsel for Wiesner Healthcare Innovation, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Edward L. Bishop | Attorney | Counsel for Wiesner Healthcare Innovation, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Nicholas S. Lee | Attorney | Counsel for Wiesner Healthcare Innovation, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Sameeul Haque | Attorney | Counsel for Wiesner Healthcare Innovation, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Bishop Diehl & Lee, Ltd. | Law Firm | Representing Wiesner Healthcare Innovation, LLCSearch in Eureka ↗ |
| Presiding judge | Judge Sharon Johnson Coleman | Judge | Illinois Southern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The default judgment encompasses liability on all six counts — three patent infringement claims, trade dress infringement, unjust enrichment, and unfair competition — with damages trebled under 35 U.S.C. § 284 and attorney’s fees awarded under § 285. The court’s willfulness finding, grounded in claim chart evidence rather than a contested trial, carries the same legal weight as a jury willfulness verdict for enforcement and collection purposes. The permanent injunction binds not only defendants but any party acting in concert with them, extending practical reach to future storefronts operated under new aliases.
US10624728B2, US11351020B2 & US11642205B2 — External Male Incontinence Clamp
The three asserted patents — US10624728B2, US11351020B2, and US11642205B2 — form a continuation family protecting external male incontinence clamp devices, a non-surgical product worn externally to manage urinary incontinence in male patients. The family spans application numbers US15/253051, US17/305844, and US16/810148, suggesting successive prosecution rounds designed to broaden or diversify claim coverage against evolving product designs. This device category occupies a commercially active segment of the urology and continence care market, where price-competitive imports are common.
A three-patent continuation family in this space is commercially significant: each successive patent may cover design variations that could otherwise serve as workarounds to the foundational claims. For medical device companies, distributors, and e-commerce sellers offering male incontinence clamps, the active enforcement demonstrated in this case — with claim charts already filed against marketplace products — raises the competitive risk profile substantially. Any product in this category entering the U.S. market should be evaluated against all three patents’ independent claims before launch.
Should you run an FTO against US10624728B2, US11351020B2 & US11642205B2?
Any company designing, importing, or selling external male incontinence clamp products in the United States — particularly via Amazon, eBay, Temu, or Walmart — should treat an FTO analysis against Wiesner’s three-patent family as a commercial necessity following this judgment. The court’s willingness to find personal jurisdiction based solely on marketplace shipping reach means that geographic distance provides no safe harbour. The claim charts already filed in this case provide a ready roadmap to the asserted claim scope.
PatSnap Eureka’s FTO Search Agent can map your product’s design against the independent and dependent claims of all three Wiesner patents simultaneously, identify claim elements that require design-around analysis, and surface related prior art that may support a validity challenge. Given the active enforcement posture evidenced by this case, commissioning an FTO before listing any male incontinence clamp product on U.S. marketplaces is the commercially prudent step.
Run a freedom-to-operate analysis on US10624728B2 to assess your product’s exposure
Run FTO in Eureka →Similar Schedule A patent cases: medical device e-commerce enforcement in Illinois
Browse comparable Schedule A patent enforcement actions in the Illinois federal courts involving medical device and healthcare product patents asserted against online marketplace sellers.
What this case signals for the medical device e-commerce IP landscape
Wiesner’s swift default judgment sets a precedent for how medical device IP holders can neutralise anonymous online infringers at scale.
Marketplace account freezing is the real enforcement lever in Schedule A cases
Orders directing Amazon, eBay, PayPal, Payoneer, Temu, and Walmart to freeze and transfer funds give patent holders immediate practical relief before defendants can withdraw assets. For IP owners with products selling on multiple platforms, building a Schedule A enforcement programme with pre-drafted account-freeze orders is now a strategic baseline, not an advanced tactic.
Treble damages and § 285 fees are reliably available when defendants default
Courts in the Northern District of Illinois have consistently found wilfulness and exceptional case status in Schedule A defaults where plaintiffs supply claim charts and screenshot evidence. Wiesner’s $10,000 base royalty plus transaction costs, trebled, shows that structuring damages arguments carefully — even in uncontested proceedings — meaningfully increases recovery per defendant and deters future infringement.
Wiesner v Individuals — key questions answered
Wiesner Healthcare Innovation LLC asserted three patents: US10624728B2, US11351020B2, and US11642205B2, all covering external male incontinence clamp devices. The patents form a continuation family filed under application numbers US15/253051, US17/305844, and US16/810148 respectively.
The court awarded $37,816.91 per defaulting defendant. This comprised a $10,000 reasonable royalty under 35 U.S.C. § 284, $2,380.95 in hypothetical negotiation transaction costs, both sums trebled, plus $674.06 in attorney’s fees per defendant under 35 U.S.C. § 285 following an exceptional case finding.
The court found personal jurisdiction because the Schedule A defendants operated interactive e-commerce stores offering shipping to Illinois residents. Screenshot evidence confirmed each storefront stood ready to ship infringing products to Illinois customers. This analysis is consistent with established Northern District of Illinois practice in Schedule A cases — marketplace shipping availability to a state is sufficient to establish purposeful availment of that forum.
The court ordered Amazon, eBay, PayPal, Payoneer, Temu, and Walmart to freeze accounts connected to defaulting defendants within seven days of the order and to release funds to Wiesner within fourteen days, up to the total damages awarded. This asset-freeze mechanism is a hallmark remedy in Schedule A patent enforcement actions.
An exceptional case finding under § 285 allows the court to award reasonable attorney’s fees to the prevailing party. In default judgment proceedings, courts in Illinois have found exceptionality where defendants wilfully infringed and failed to appear, leaving allegations uncontested. Here, the finding resulted in $14,155.33 in total attorney’s fees across 21 defendants. The designation also signals that Wiesner’s patents are treated as credible and actively enforced, which may deter future infringement.
PatSnap Eureka searches patents and litigation data to answer instantly.